Amyotrophic lateral sclerosis (ALS) is probably one of the most devastating diagnoses that we should all hope to never hear. Also known as Lou Gehrig’s disease, or motor neuron disease, ALS is a progressive neurodegenerative disorder that affects the nerve cells in the brain and spinal cord that are responsible for controlling voluntary muscles. As the disease advances, both upper and lower motor neurons degenerate and die, leading to muscle weakness, twitching, atrophy, stiffness, and eventually paralysis of the muscles involved in movement, speech, swallowing, and breathing.
There is no known cure for ALS. Treatments are limited to managing symptoms, improving quality of life, and in some cases, modestly slowing progression. Science-based or evidence-based medicine is limited to what the evidence actually shows. In contrast there is no lack of “innovative” therapies, supplements, and other treatments that are marketed as supportive, restorative, or even disease-modifying. Many are sold directly to patients, often at significant cost, and in the absence of robust, credible published evidence that they offer meaningful benefits to patients.
Recent media coverage in Canada has highlighted just how vulnerable people with ALS can be to these claims. A CBC investigation reported on an American patient who sought treatment at a private clinic in Saskatchewan, spending thousands on unproven interventions after selling her home to pay for treatment. According to the CBC, her condition continued to deteriorate, and she later died after returning to the United States. The details are tragic, but the story itself is sadly not unique. It illustrates the desperation that accompanies ALS diagnosis, like many terminal diagnoses, and the persistent market for treatments that promise more than a review of the evidence can support.
Recognized Treatments
Despite decades of research, and many millions of dollars invested, evidence-based treatment options for ALS remain very limited. No treatment has been shown to reverse motor neuron loss or stop disease progression. However, a small number of therapies have been show to offer modest benefits.
Riluzole was the first medication (approved in 1995) shown to actually alter the course of the disease. ALS involves progressive motor neuron degeneration, with glutamate-mediated excitotoxicity believed to be one possible mechanism. Excess glutamate overstimulates neurons, causing cellular damage. Riluzole’s exact mechanism of action is unclear, but it appears to reduce this excitotoxicity. Clinical trials and long-term observational studies suggest that riluzole modestly prolongs survival, typically by several months. It does not improve muscle strength or reverse established disability. Riluzole is a standard, first-line treatment of ALS.
Edaravone has been shown to provide a modest slowing of functional decline in a subset of patients with ALS by slowing the loss of physical function, and helping some patients live longer. Edaravone does not stop ALS, but in some patients it can modestly slow the disease’s progression. Its benefits in the broader ALS population is unclear.
Other more recently approved therapies have generated headlines but their role remains uncertain. Some have been approved under accelerated or conditional pathways based on surrogate endpoints or limited clinical data. As I have discussed recently, there are significant risks in approving drugs based on surrogate endpoints. Based on the accumulated evidence, benefits from these new therapies are expected to be modest, and ongoing studies will eventually determine if these products actually provide meaningful benefits.
Supportive care
For most people with ALS, the greatest improvements in survival and quality of life come not from disease-modifying drugs, but from comprehensive supportive care delivered through multidisciplinary ALS clinics.
Key components include:
- Non-invasive ventilation, which improves survival and reduces symptoms of respiratory failure
- Nutritional support, including timely placement of feeding tubes when appropriate
- Management of symptoms such as spasticity, pain and muscle cramps
- Physical, occupational, and speech therapy to preserve function and communication for as long as possible
These specialized ALS clinics are associated with longer survival compared with fragmented or generalist care.
What ALS treatments can offer
This section is brief, because the number of proven therapies is maddeningly small. Existing treatments may slow progression, ease symptoms, and extend life modestly. To date nothing has been proven to cure ALS, regenerate motor neurons, or restore function once it has been lost.
This large gap between what medicine can realistically offer today, and what patients and their families understandably want creates the perfect environment for treatments that offer and promise hope. When hope isn’t backed by good evidence, it may result in lost time, disappointment, wasted resources, and even harm.
Supplements and ALS
When faced with a disease like ALS, and the limited medication options, it is understandable that patients and their families will look for anything that might help. Supplements are especially appealing. They are widely marketed (often with few restrictions on claims) and generally perceived to be “natural” and “safe”.
Many supplements have been studied in clinical trials. As is common in dietary supplement research, positive trials are usually small, short-term, and poorly designed. When larger or better-designed trials have been conducted, results have generally been negative or unclear.
Examples include:
- Antioxidants such as vitamin E and vitamin C do not slow disease progression or improve survival in randomized trials, suggesting that targeting oxidative stress is not an effective approach.
- Vitamin B12, particularly in high doses. Limited studies have not demonstrated clear, consistent benefit.
- Omega-3 fatty acids, often promoted for neuroprotection, look promising in observational research. However, based on prospective trials, they remain unproven.
- Herbal products and “proprietary blends” are frequently marketed with vague statements about “cellular support” or “neuroprotection,” but usually have no evidence to support them.
No supplement has been shown to meaningfully slow disease progression, improve survival, or restore function in ALS. However, clinicians may also feel uncomfortable discouraging their use, particularly when patients are highly motivated, the proven treatments are modestly effective and the perceived risks seem low. This may unintentionally reinforce the idea that supplements are at least potentially helpful.
The idea that supplements are harmless is often wrong, as has been noted many times on this blog. Product regulation is so weak in many countries that labels may not reliably tell you the actual contents. Even if what’s on the label is actually in the bottle, supplements can cause adverse effects, interact with prescription medications, or interfere with nutrition and metabolism. Financial toxicity is a known side effect too. Supplement regimens can be expensive.
Conclusion: False hope can be compelling
ALS remains a disease with few effective treatment options. This has driven interest in anything else that might offer benefit. Evidence‑based treatments may provide only modest improvements, but these gains are measurable, clinically meaningful, and have been proven in clinical trials. In contrast, dietary supplements have been used for decades and continue to be widely marketed without demonstrating any ability to alter the trajectory of ALS in any substantive way. The appeal of unproven approaches is understandable, but without credible evidence, they continue to divert attention and resources from treatments that can genuinely help, and, as recent reporting illustrated, drive expectations that ultimately cannot be met.